The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI).
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Brian Jensen
Medicine - Cardiology
Clinical or Medical
Interventional
Heart and Circulation
22-2216
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
